Neutrophil heterogeneity in cancer
| Species | Tumor | Populations | Signatures and/or functions | Reference |
|---|---|---|---|---|
| Mouse | AB12, LKR, and TC1 | N1 and N2 | N1: anti-tumor; N2: pro-tumor | 54 |
| 4T1 | LDN and HDN | HDNs: cytotoxic capability toward tumor cells; LDNs: impaired neutrophil function and immunosuppressive properties | 57 | |
| MMTV-PyMT transgenic mouse model of breast cancer | C0, C2, C4, C5, C7, and C8 | C0: Camp17 and Ly6g; C2: Il1β and Arg2; C4, C5: Cebpe and Retnlg; C7, C8: Tuba1b and Cdc20. | 58 | |
| LLC | Classical PMNs, PMN-MDSCs, and activated PMN-MDSCs | Classical PMNs: account for almost 95% neutrophils in control spleen; PMN-MDSCs: Ngp, Ltf, Cd177, Anxa1, Mmp8, S100a8, S100a9, Cebpe, Ltb4r1, and Cybb; activated PMN-MDSCs: Ccl4, Ccl3, Cxcl2, Cxcl3, Spp1, Il1b, Nfkbia, Socs3, Mif, Klf6, Atf3, Ptgs2, and Xbp1. potent immune suppressive activity | 61 | |
| KP1.9 | mN1–mN6 | mN1: Mmp8, Mmp 9, S100a8, S100a 9, and Adam8; mN2: Ifit1, Irf7, and Rsad2; mN3: Cxcl3; mN4: Pald1; mN5: Ccl3, Csf1, Cstb, and Irak2; mN6: Fcnb and Ngp | 59 | |
| Human | NSCLC | hN1–hN5 | hN1: MMP8, MMP9, S100A8, S100A 9, and ADAM8; hN2: IFIT1, IRF7, and RSAD2; hN3: CASS4; hN4: CTSC; hN5: CCL3, CSF1, CTSB, and IRAK2 | 59 |
| Melanoma | hNeP and Cneut1–Cneut5 | hNep: CD117+CD66b+CD38+ neutrophil progenitors; Cneut1: CD16dimCD62 Lbright band cell; Cneut2: terminally differentiated, mature neutrophils; Cneut3: CXCR4+CD49d+ | 60 | |
| CD62 Llo aged neutrophils; Cneut4: no specific features; Cneut5: immature neutrophils; Cneut6: CD16dimCD62 Lbright band cells | ||||
| Pancreatic ductal adenocarcinoma | TNA0–TNN5 | TAN-0: no cluster-specific distinctive features; TAN-1: terminally differentiated pro-tumor subpopulation; TAN-2: inflammatory subpopulation; TAN-3: transitional stage subpopulation; TAN-4: expression of interferon-stimulated genes; TAN-5: undefined subpopulation of low-quality cells | 62 | |
| NSCLC | TAN1–4/ NAN1–2 | TAN1: CXCL8, CXCL1, CXCL2, ICAM1, and CD44; TAN2: HLA-DRA, CD74, and HLA-DPB1; TAN3: PLIN2, PLPP, MAP1, LC3B, and PLAU; TAN4: RPL10, RPS2, RPS18, RPL3. NAN1: S100A12, PAD14, PROK2, and MMP9; NAN2: similar to NAN1 cluster, and decreased expression of S100A12, MME, and PROK2 | 63 |